Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Nephrology
•
Onconephrology
•
Tumor Lysis Syndrome
•
Hospital Medicine
Do you recommend testing for G6PD deficiency in those with whom rasburicase for tumor lysis syndrome is indicated?
Answer from: at Academic Institution
G6PD deficiency is a contraindication to the use of rasburicase and should be tested for prior to the use of this drug.
Sign in or Register to read more
Answer from: at Community Practice
You're supposed to test, but most do not. It's X-linked, so males are more susceptible. Certain populations are too: sub-Saharan Africa, the Mediterranean, and Southeast Asia.
Sign in or Register to read more
17203
17204
Related Questions
How often do you check fibrinogen levels and when do you administer FFP for patients with AKI requiring plasma exchange?
What is your approach to weaning dialysis in a patient with AKI on CKD and CHF who now has resolved AKI but a history of recurrent episodes of decompensated heart failure?
What would be your approach to managing severe ANCA-associated vasculitis in a patient who is also septic from a bacterial infection?
Would you recommend starting tolvaptan at 7.5 mg per day, which is half the typical starting dose, to reduce the risk of overcorrection in an inpatient with SIADH and a serum sodium level of 122 mEq/L?
How do you recommend incorporating B-lines on lung POCUS as part of evaluating a patient's volume status?
Would you continue to monitor urinary protein levels and dose adjust axitinib in a patient with metastatic malignancy who is now dialysis dependent but has residual renal function?
What is your approach to managing concurrent severe SIADH and large-volume malignant ascites when aggressive volume removal appears to exacerbate both symptoms and hyponatremia?
Would you recommend administering IV amino acids prior to cardiac surgery with cardiopulmonary bypass, given recent trial findings of improved AKI rates but no significant difference in kidney-replacement therapy with IV amino acids?
Do you recommend any CRRT prescription changes for optimal clearance for patients with AKI who are on a reduced blood flow rate due to concurrent regional citrate anticoagulation?
Do you avoid performing urine microscopy in patients with AKI who have COVID-19 given concern for potential aerosolization?